WIN $150 GIFT VOUCHERS: ALADDIN'S GOLD

Close Notification

Your cart does not contain any items

Revealing Uncharted Biology with Single Cell Multiplex Proteomic Technologies

Applications

Wendy Fantl (Associate Professor (Research), Department of Urology, Stanford University, CA, USA)

$181.95

Paperback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
27 June 2024
Revealing Uncharted Biology with Single Cell Multiplex Proteomic Technologies: Applications Healthy tissues and organs rely on the precise coordination of diverse cell types, each responding to external and internal signals. Disease disrupts this coordination. Since proteins drive cellular function, analyzing their abundance and activation states in single cells helps identify key cell populations in health and disease. Bulk protein analyses mask critical differences between individual cells. Additionally, the arrangement of cells into neighborhoods through cell-cell interactions is essential for tissue function. Over the last decade, single-cell proteomic phenotyping combined with positional information has become crucial for understanding biology in health and disease. This has led to the development of multiple technology platforms, profoundly impacting fields including developmental biology, cancer biology, immunology, neuroscience, and drug discovery.

This book focuses on the application of single-cell multiplex proteomic platforms to various biological systems. These platforms have proved to be essential in biomedical research, advancing our understanding of complex biological systems at the cellular level. Compelling studies where authors use these technologies to answer previously unanswerable questions are featured. Exploring this ""Uncharted Biology"" opens new avenues for scientific inquiry and clinical translation, covering areas including oncology, immunology, metabolomics, stem cell research, preclinical models, and translational research. The initial chapters discuss incorporating these technologies into core facilities and consortia, providing access for multiple users and integrating datasets from other omics technologies. The following chapters cover applications in diverse areas such as muscle stem cell function in skeletal muscle regeneration, metabolic regulome profiling, translational studies, developing predictive biomarkers for patients receiving immune checkpoint inhibitors, and pre-clinical studies of lung cancer. These applications demonstrate how advanced single cell proteomic technologies are reshaping our understanding of complex biological systems and enhancing clinical translation.

Revealing Uncharted Biology with Single Cell Multiplex Proteomic Technologies: Applications highlights the transformative benefits of single-cell proteomics, offering insights into cellular mechanisms underlying health and disease and inspiring further exploration into ""Uncharted Biology."" It is an essential resource for researchers, clinicians, and students aiming to advance biomedical science and improve therapeutic outcomes.
Edited by:  
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 235mm,  Width: 191mm, 
Weight:   440g
ISBN:   9780128222133
ISBN 10:   0128222131
Pages:   202
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active

Wendy J. Fantl, PhD, is currently Head of Systems-level Translational Discovery Research in the Department of Discovery Sciences in Biomedical Research at Novartis. Wendy earned her Ph.D. in protein biochemistry from Rockefeller University and completed her postdoctoral studies at University of California, San Francisco focusing on receptor tyrosine kinase signal transduction. She spent over a decade at Chiron Corporation, where she applied her signaling expertise to targeting kinases. Subsequently, as Vice President of Cancer Biology at Nodality, she developed diagnostic phospho-flow tests for leukemias. In 2010, Wendy returned to academia and joined Stanford University, where her lab applied single cell multiplex proteomic technologies focusing on human high-grade serous ovarian cancer and clear cell renal carcinoma focusing on the tumor immune microenvironment and the DNA damage response. Wendy joined Novartis in 2022 to lead a team dedicated to using these technologies to further the mechanistic understanding of drug responses in patients, aligning with her commitment to patient care.

See Also